Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular mechanisms and therapeutic targets for diabetic kidney disease
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, et al.
Kidney International (2022) Vol. 102, Iss. 2, pp. 248-260
Open Access | Times Cited: 294

Showing 26-50 of 294 citing articles:

Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients
Kumar Sharma, Guanshi Zhang, Jens Hansen, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 20
Open Access | Times Cited: 24
Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes
Jianjun Liu, Jianhong Ching, Hai Ning Wee, et al.
Diabetes Care (2023) Vol. 46, Iss. 12, pp. 2223-2231
Open Access | Times Cited: 23
Research progress on multiple cell death pathways of podocytes in diabetic kidney disease
Can Yang, Zhen Zhang, Jieting Liu, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 22
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3969-3969
Open Access | Times Cited: 13
Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment
Shiyi Shen, Huiyun Zhong, Xiaoshi Zhou, et al.
Pharmaceutical Biology (2024) Vol. 62, Iss. 1, pp. 222-232
Open Access | Times Cited: 12
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 10
tRF3-IleAAT reduced extracellular matrix synthesis in diabetic kidney disease mice by targeting ZNF281 and inhibiting ferroptosis
Yunyang Qiao, Jialing Ji, Wei-ling Hou, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 5, pp. 1032-1043
Closed Access | Times Cited: 9
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
Stefan R. Bornstein, Dick de Zeeuw, Hiddo J.L. Heerspink, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2128-2138
Open Access | Times Cited: 9
Lipid metabolism disorder in diabetic kidney disease
Yi-Zhen Han, Bo-Xuan Du, Xingyu Zhu, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 9
Sirt6 overexpression relieves ferroptosis and delays the progression of diabetic nephropathy via Nrf2/GPX4 pathway
Lingyu Du, Canghui Guo, Shengnan Zeng, et al.
Renal Failure (2024) Vol. 46, Iss. 2
Open Access | Times Cited: 9
Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway
Xinwang Zhu, Congxiao Zhang, Linlin Liu, et al.
International Journal of Molecular Medicine (2024) Vol. 53, Iss. 3
Open Access | Times Cited: 8
Association of Systemic Immune-Inflammation Index and Systemic Inflammation Response Index with Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus.
Wenli Liu, Shuran Zheng, Xiaogang Du
PubMed (2024) Vol. 17, pp. 517-531
Closed Access | Times Cited: 8
Advances in kidney disease: pathogenesis and therapeutic targets
Vincent Boima, Alex Baafi Agyekum, Khushali Ganatra, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 1
Klotho’s impact on diabetic nephropathy and its emerging connection to diabetic retinopathy
Anqi Tang, Yu Zhang, Ling Wu, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 21
Experimental Models to Study Diabetes Mellitus and Its Complications: Limitations and New Opportunities
Beatriz Martín-Carro, Javier Donate‐Correa, Sara Fernández-Villabrille, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10309-10309
Open Access | Times Cited: 19
Nephroprotective Properties of Antidiabetic Drugs
Christian Gerdes, N Müller, Günter Wolf, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3377-3377
Open Access | Times Cited: 16
The regulatory role of miRNA and lncRNA on autophagy in diabetic nephropathy
Siming Yu, Yue Li, Xinxin Lu, et al.
Cellular Signalling (2024) Vol. 118, pp. 111144-111144
Closed Access | Times Cited: 7
The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through ‘stacking’ of drugs from different classes
David S.H. Bell, Terri Jerkins
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2046-2053
Closed Access | Times Cited: 7
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Michael Cooreman, Luisa Vonghia, Sven Francque
Diabetes Research and Clinical Practice (2024) Vol. 212, pp. 111688-111688
Closed Access | Times Cited: 7
A graminan type fructan from Achyranthes bidentata prevents the kidney injury in diabetic mice by regulating gut microbiota
Huayang Si, Yimeng Chen, Dejun Hu, et al.
Carbohydrate Polymers (2024) Vol. 339, pp. 122275-122275
Closed Access | Times Cited: 7
Molecular mechanism of renal lipid accumulation in diabetic kidney disease
Zhengying Fang, Ruijie Liu, Jingyuan Xie, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 11
Open Access | Times Cited: 7
(Pro)renin receptor mediates tubular epithelial cell pyroptosis in diabetic kidney disease via DPP4-JNK pathway
Shiying Xie, Shicong Song, Sirui Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Critical role of FGF21 in diabetic kidney disease: from energy metabolism to innate immunity
Yingnan Liang, Qi Chen, Yue Chang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes
Tong‐Tong Liu, Hailing Zhao, Ying Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
The Difference Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and Risk of Diabetic Microvascular Complications Among Adults With Diabetes: A Population-Based Cohort Study
Daijun He, Bixia Gao, Jinwei Wang, et al.
Diabetes Care (2024) Vol. 47, Iss. 5, pp. 873-880
Open Access | Times Cited: 6

Scroll to top